



Concert Pharmaceuticals to Present at Upcoming Investor Conferences

August 29, 2019

LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 29, 2019-- [Concert Pharmaceuticals, Inc.](https://www.concertpharma.com) (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:

- The H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 at 8:45 a.m. ET in New York, NY;
- The 3rd Annual Janney Healthcare Conference on September 10, 2019 at 9:05 a.m. ET in New York, NY; and
- The Cantor Global Healthcare Conference on October 3, 2019 at 5:20 p.m. ET in New York, NY.

Live webcasts of the presentations may be accessed in the Investors section of the Company's website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the conference webcasts will be available on Concert's website for two weeks following the presentations.

About Concert

[Concert Pharmaceuticals](https://www.concertpharma.com) is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company's approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert's pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at [@ConcertPharma](https://twitter.com/ConcertPharma) or on [LinkedIn](https://www.linkedin.com/company/concert-pharmaceuticals).

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190829005072/en/>

Source: Concert Pharmaceuticals, Inc.

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com